Showing results (141-150 of 186) with videos related to

Sort By:
Pageof 19
Liver International : Official Journal of the International Association for the Study of the Liver|September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCCTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and BevacizumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre StudyTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 11, 2024
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practiceAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Liver Cancer|October 9, 2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular CarcinomaKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology|August 10, 2025
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular CarcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Oncology|February 3, 2025
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not SufficientAtsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
Pageof 19